We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > KOL

News List

KOL Views Preview: AbbVie’s ABBV-951 works but will PD patients use it? FirstWordPharma
November 01, 2021
ABBV-951 was expected to work better than oral levodopa/carbidopa and it did not disappoint in a Phase III trial for advanced Parkinson’s disease (PD).
Analyst answers — What lies ahead for malignant melanoma? firstwordpharma
December 05, 2018
What changes do key opinion leaders (KOLs) see coming for malignant melanoma (MM) treatment?
KOL Views: How does Opdivo’s stumble shift the balance of power in SCLC? biospectrumasia
October 17, 2018
KOL Views Imfinzi Keytruda Opdivo Tecentriq AstraZeneca BMS Merck & Co. Roche EMA FDA Lung Cancer Pulmonary/Respiratory Medicine Marketing & Sales Medical Affairs